Physician profile
Mark C Hoffman
NPI 1093883738
$1,302.98
in general payments reported to CMS, 2019-2025
26 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $86.89 · 2022: $56.34 · 2023: $284 · 2024: $308 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.03 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $137.33 | 2019-2024 | Zepbound, Mounjaro, Lyumjev |
| Astrazeneca Pharmaceuticals Lp | $90.48 | 2019-2025 | Breztri |
| Abbvie INC. | $76.68 | 2023-2024 | |
| Pfizer INC. | $74.39 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.98 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.89 | 2019-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $62.66 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $59.50 | 2025 | Voquezna |
| Amgen INC. | $57.47 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $45.02 | 2019-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $42.26 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.95 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $41.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.59 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $22.55 | 2023 | Qelbree |
| Exact Sciences Corporation | $22.18 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $19.27 | 2019 | |
| Edwards Lifesciences Corporation | $18.43 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Hologic Sales and Service, LLC | $16.97 | 2023 | Aptima, Thinprep 2000 Processor |
| Sanofi-Aventis U.S. LLC | $16.86 | 2019 | |
| Radius Health, INC. | $16.28 | 2023 | Tymlos |
| Abiomed | $15.45 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $14.45 | 2019 | |
| Amarin Pharma, INC. | $12.06 | 2020 | |
| Linus Health, INC. | $11.96 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.